Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTRafael Holdings, Inc.'s latest supported as-filed period reports revenue of $179,000, 50.6% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -4069.27% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -50.55% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 154.19% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value -3837.99% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 2711.17% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -19.6% from the comparable as-filed period.
Inventory changed -4.2% from the comparable as-filed period.
Net income changed +11.6% from the comparable as-filed period.
Operating income changed -16.2% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
RFL · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-328798SEC ↗8-KJul 8, 2026Period Jul 8, 20260001213900-26-076411SEC ↗4Jun 23, 2026Period Jun 21, 20260001193125-26-279350SEC ↗4Jun 16, 2026Period Jun 13, 20260001193125-26-272548SEC ↗10-QJun 11, 2026Period Apr 30, 20260001213900-26-067560SEC ↗8-KJun 11, 2026Period Jun 11, 20260001213900-26-067555SEC ↗8-KJun 10, 2026Period Jun 10, 20260001213900-26-067083SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 29, 2026Filed Jul 31, 2026 | JONAS HOWARD SExec Chairman, CEO & President | Grant Or AwardDirect | 54,945 | $3 | $150,000 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.sbc_revenue_ratio
Raw value 96.09% · OPTIONAL
Operating margin changed -220456 basis points from the comparable as-filed period.
Research & development changed +61.6% from the comparable as-filed period.
Revenue changed -50.6% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-04-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-046380